Fig. 4: AURKA inhibition disrupts c-MET and CSC properties.
a Western blot illustrating c-MET levels after treatment with alisertib and/or cetuximab in SW48 and C10 cell lines. Tubulin was used as loading control. Results are plotted as the average ± SD of all the biological replicates and were normalized to the EGF condition. *p < 0.05, **p < 0.01, ***p < 0.001 (n = 3), one-way ANOVA (n = 4). b Colony formation assay following treatment with alisertib and/or cetuximab in SW48 and C10 cell lines. Results are plotted as the average ± SD of all the biological replicates. *p < 0.05, **p < 0.01 (n = 3), one-way ANOVA. c. ALDH1 relative activity after treatment with alisertib and/or cetuximab in SW48 and C10 cell lines. Results were normalized to the control condition for each cell line and are plotted as the average± SD of all the biological replicates (n = 3) **p < 0.01, ***p < 0.001, one-way ANOVA. d SOX2 gene expression after treatment with alisertib and/or cetuximab in SW48 and C10 cell lines. Results were normalized to the control condition in each cell line and are plotted as the average ± SD of all the biological replicates (n = 3). *p < 0.05, **p < 0.01 (n = 3), one-way ANOVA. e. Spheroid size (mm3) ability after treatment with alisertib and/or cetuximab in C10 cell line. Results are plotted as the average ± SD of all the biological replicates *p < 0.05, **p < 0.01 (n = 3), one-way ANOVA. CTR Control, ALS Alisertib, CTX Cetuximab, COM Combined.
